Norcantharidin combined with ABT-737 for hepatocellular carcinoma: Therapeutic effects and molecular mechanisms

Figure 1 Change in cell proliferation inhibition rate after 48 h of treatment with different concentrations of norcantharidin. A: The change of cell proliferation inhibition rate in HepG2 cells; B: The change of cell proliferation inhibition rate in SMMC-7721 cells.

Figure 2 Change in cell proliferation inhibition rate after 48 h of treatment with different concentrations of ABT-737 or with ABT-737 combined with different concentrations of norcantharidin (15 μm, 30 μm, 60 μm). A: The change of cell proliferation inhibition rate in HepG2 cells; B: The change of cell proliferation inhibition rate in SMMC-7721 cells.

Figure 3 Expression of Mcl-1 in cells after treatment with different concentrations of norcantharidin.

Figure 4 Expression of cytochrome C in HepG2 cells and SMMC-7721 cells after treatment with ABT-737 and norcantharidin detected by Western blotting. A: The expression of cytochrome C in HepG2 cells; B: The expression of cytochrome C in SMMC-7721 cells.

Figure 5 Apoptosis of HepG2 and SMMC-7721 cells detected by flow cytometry after treatment for 48 h. A: The apoptosis of HepG2 cells after treatment for 48 h; B: The apoptosis of SMMC-7721 cells after treatment for 48 h.